SMT’s Supraflex Cruz DES Approved in Australia

September 27, 2024—Sahajanand Medical Technology Pvt Ltd (SMT), which is based in Mumbai, India, announced that its flagship drug-eluting stent (DES), Supraflex Cruz, has received regulatory approval from the Therapeutic Goods Administration in Australia for the treatment of coronary artery disease.

According to SMT, the Supraflex Cruz DES is designed to deliver a combination of sirolimus and a biodegradable polymer that ensures optimal drug release and vessel healing. The stent’s design allows for greater flexibility, reduced injury to the arterial wall, and faster endothelial healing, resulting in better patient outcomes.

The company stated that the device’s design provides access to difficult and tortuous lesions. The stent retains the benefits of Supraflex stents or the previous Supra family of stents: thin struts, a blend of the SMT’s biodegradable polymers to release the drug, high radial strength, and low crossing profile. Supraflex Cruz DES’s size matrix includes diameters from 2.0 to 4.5 mm and lengths from 8 to 48 mm.

In 2019, SMT announced European CE Mark approval for the Supraflex Cruz DES.